An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
- Resource Type
- Article
- Source
- In
The Lancet 21-27 January 2023 401(10372):204-214 - Subject
Primary Research Articles - Language
- ISSN
- 0140-6736